*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter - as a primary diagnosis code | T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter - as a primary or secondary diagnosis code | |
|---|---|---|
| OUTCOMES | ||
| Avg. LOS | 6.83 | |
| Readmission Rate (%) | 32.05 | |
| Unplanned Readmission Rate (%) | 17.4 | |
| Mortality Rate (%) | ||
| SNF Discharge Rate (%) | ||
| Home Discharge Rate (%) | ||
| PAYMENTS AND CHARGES | ||
| Total Medicare Payments | ||
| Payment Per Day | ||
| Payment Per Hospitalization | ||
| Total Medicare Charges | ||
| Avg. Charges | ||
| MARKET SIZING & INCIDENCE RATES | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - All) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - All) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Yes) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Yes) | ||
| Total National Projected Hospitalizations - Annualized (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations - Oct 2015 to Sep 2018 (Present on Admission - Not Y) | ||
| Total Medicare Hospitalizations after Exclusion | ||
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 918: POISONING AND TOXIC EFFECTS OF DRUGS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 917: POISONING AND TOXIC EFFECTS OF DRUGS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|
| Total Hospitalizations at DRG | 71,748 | |
| Total Hospitalizations with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 387 | |
| DRG Share of Total Hospitalizations | 0.22 | |
| % of Total ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter in DRG | 54.82 | |
| Avg LOS at DRG | 2.93 | |
| Avg LOS with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 3.27 | |
| Readmission Rate at DRG | 33.86 | |
| Readmission Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 26.72 | |
| Unplanned Readmission Rate at DRG | 10.34 | |
| Unplanned Readmission Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 17.99 | |
| Total Medicare payments at DRG | $313,351,773 | |
| Total Medicare payments with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $1,716,195 | |
| Total Medicare payment per Day at DRG | $1,489 | |
| Total Medicare payment per Day with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $1,357 | |
| Total Medicare payment per Hospitalization at DRG | $4,367 | |
| Total Medicare payment per Hospitalization with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $4,435 | |
| Total Medicare Charges at DRG | $1,750,048,705 | |
| Total Medicare Charges with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $9,970,328 | |
| Avg Charges at DRG | $24,392 | |
| Avg Charges with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $25,763 | |
| Mortality Rate at DRG | 0.22 | |
| Mortality Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | NA | |
| SNF Discharge Rate at DRG | 7.61 | |
| SNF Discharge Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 5.43 | |
| Home Discharge Rate at DRG | 51.88 | |
| Home Discharge Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 75.19 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| KARMANOS CANCER CENTER | 4100 JOHN R ST | DETROIT | MI | 48201 | 11 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 871: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 809: MAJOR HEMATOLOGICAL AND IMMUNOLOGICAL DIAGNOSES EXCEPT SICKLE CELL CRISIS AND COAGULATION DISORDERS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 808: MAJOR HEMATOLOGICAL AND IMMUNOLOGICAL DIAGNOSES EXCEPT SICKLE CELL CRISIS AND COAGULATION DISORDERS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH COMPLICATION OR COMORBIDITY (CC) | DRG 392: ESOPHAGITIS, GASTROENTERITIS AND MISCELLANEOUS DIGESTIVE DISORDERS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 1,808,415 | ||||
| Total Hospitalizations with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 27,699 | ||||
| DRG Share of Total Hospitalizations | 5.5 | ||||
| % of Total ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter in DRG | 9.13 | ||||
| Avg LOS at DRG | 6.34 | ||||
| Avg LOS with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 6.91 | ||||
| Readmission Rate at DRG | 24.2 | ||||
| Readmission Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 30.12 | ||||
| Unplanned Readmission Rate at DRG | 16.78 | ||||
| Unplanned Readmission Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 20.08 | ||||
| Total Medicare payments at DRG | $21,288,214,047 | ||||
| Total Medicare payments with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $345,918,506 | ||||
| Total Medicare payment per Day at DRG | $1,857 | ||||
| Total Medicare payment per Day with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $1,808 | ||||
| Total Medicare payment per Hospitalization at DRG | $11,772 | ||||
| Total Medicare payment per Hospitalization with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $12,488 | ||||
| Total Medicare Charges at DRG | $107,155,481,388 | ||||
| Total Medicare Charges with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $1,900,041,781 | ||||
| Avg Charges at DRG | $59,254 | ||||
| Avg Charges with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $68,596 | ||||
| Mortality Rate at DRG | 12.11 | ||||
| Mortality Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 12.3 | ||||
| SNF Discharge Rate at DRG | 27.18 | ||||
| SNF Discharge Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 13.65 | ||||
| Home Discharge Rate at DRG | 25.81 | ||||
| Home Discharge Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 36.19 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 394: OTHER DIGESTIVE SYSTEM DIAGNOSES WITH COMPLICATION OR COMORBIDITY (CC) | DRG 683: RENAL FAILURE WITH COMPLICATION OR COMORBIDITY (CC) | DRG 682: RENAL FAILURE WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 193: SIMPLE PNEUMONIA AND PLEURISY WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 872: SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 130,303 | ||||
| Total Hospitalizations with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 6,044 | ||||
| DRG Share of Total Hospitalizations | 0.4 | ||||
| % of Total ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter in DRG | 1.99 | ||||
| Avg LOS at DRG | 3.94 | ||||
| Avg LOS with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 4.55 | ||||
| Readmission Rate at DRG | 20.31 | ||||
| Readmission Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 25.93 | ||||
| Unplanned Readmission Rate at DRG | 14.61 | ||||
| Unplanned Readmission Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 18.53 | ||||
| Total Medicare payments at DRG | $778,992,768 | ||||
| Total Medicare payments with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $38,267,653 | ||||
| Total Medicare payment per Day at DRG | $1,517 | ||||
| Total Medicare payment per Day with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $1,390 | ||||
| Total Medicare payment per Hospitalization at DRG | $5,978 | ||||
| Total Medicare payment per Hospitalization with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $6,332 | ||||
| Total Medicare Charges at DRG | $4,222,655,144 | ||||
| Total Medicare Charges with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $201,202,027 | ||||
| Avg Charges at DRG | $32,406 | ||||
| Avg Charges with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $33,290 | ||||
| Mortality Rate at DRG | 0.93 | ||||
| Mortality Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 0.55 | ||||
| SNF Discharge Rate at DRG | 14.17 | ||||
| SNF Discharge Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 7.83 | ||||
| Home Discharge Rate at DRG | 60.3 | ||||
| Home Discharge Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 68.51 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 641: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 016: AUTOLOGOUS BONE MARROW TRANSPLANT WITH COMPLICATION OR COMORBIDITY (CC)/MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 846: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 840: LYMPHOMA AND NON-ACUTE LEUKEMIA WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 391: ESOPHAGITIS, GASTROENTERITIS AND MISCELLANEOUS DIGESTIVE DISORDERS WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 310,318 | ||||
| Total Hospitalizations with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 5,141 | ||||
| DRG Share of Total Hospitalizations | 0.94 | ||||
| % of Total ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter in DRG | 1.7 | ||||
| Avg LOS at DRG | 3.19 | ||||
| Avg LOS with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 3.44 | ||||
| Readmission Rate at DRG | 20.19 | ||||
| Readmission Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 28.74 | ||||
| Unplanned Readmission Rate at DRG | 13.62 | ||||
| Unplanned Readmission Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 19.76 | ||||
| Total Medicare payments at DRG | $1,415,392,709 | ||||
| Total Medicare payments with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $24,629,776 | ||||
| Total Medicare payment per Day at DRG | $1,431 | ||||
| Total Medicare payment per Day with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $1,392 | ||||
| Total Medicare payment per Hospitalization at DRG | $4,561 | ||||
| Total Medicare payment per Hospitalization with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $4,791 | ||||
| Total Medicare Charges at DRG | $7,113,640,596 | ||||
| Total Medicare Charges with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $131,971,493 | ||||
| Avg Charges at DRG | $22,924 | ||||
| Avg Charges with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $25,670 | ||||
| Mortality Rate at DRG | 0.63 | ||||
| Mortality Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 0.68 | ||||
| SNF Discharge Rate at DRG | 19.76 | ||||
| SNF Discharge Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 9.98 | ||||
| Home Discharge Rate at DRG | 50.47 | ||||
| Home Discharge Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 59.74 |
*Readmission Rate is calculated from Oct 2015 to Aug 2018 and all other Quality Outcomes are calculated from Oct 2015 to Sep 2018.
| DRG 640: MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM , FLUIDS AND ELECTROLYTES WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 393: OTHER DIGESTIVE SYSTEM DIAGNOSES WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 194: SIMPLE PNEUMONIA AND PLEURISY WITH COMPLICATION OR COMORBIDITY (CC) | DRG 291: HEART FAILURE AND SHOCK WITH MAJOR COMPLICATION OR COMORBIDITY (MCC) | DRG 812: RED BLOOD CELL DISORDERS WITHOUT MAJOR COMPLICATION OR COMORBIDITY (MCC) | |
|---|---|---|---|---|---|
| Total Hospitalizations at DRG | 231,812 | ||||
| Total Hospitalizations with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 4,412 | ||||
| DRG Share of Total Hospitalizations | 0.71 | ||||
| % of Total ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter in DRG | 1.45 | ||||
| Avg LOS at DRG | 4.41 | ||||
| Avg LOS with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 5.29 | ||||
| Readmission Rate at DRG | 29.12 | ||||
| Readmission Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 31.66 | ||||
| Unplanned Readmission Rate at DRG | 22.82 | ||||
| Unplanned Readmission Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 21.5 | ||||
| Total Medicare payments at DRG | $1,743,376,418 | ||||
| Total Medicare payments with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $34,688,552 | ||||
| Total Medicare payment per Day at DRG | $1,704 | ||||
| Total Medicare payment per Day with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $1,486 | ||||
| Total Medicare payment per Hospitalization at DRG | $7,521 | ||||
| Total Medicare payment per Hospitalization with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $7,862 | ||||
| Total Medicare Charges at DRG | $8,543,867,896 | ||||
| Total Medicare Charges with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $183,140,496 | ||||
| Avg Charges at DRG | $36,857 | ||||
| Avg Charges with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | $41,510 | ||||
| Mortality Rate at DRG | 2.89 | ||||
| Mortality Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 3.58 | ||||
| SNF Discharge Rate at DRG | 22.92 | ||||
| SNF Discharge Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 15.28 | ||||
| Home Discharge Rate at DRG | 43.02 | ||||
| Home Discharge Rate with ICD T451X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter | 43.63 |
| Hospital Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030 | 3,795 |
| BARNES JEWISH HOSPITAL | 1 BARNES-JEWISH HOSPITAL PLZ | SAINT LOUIS | MO | 63110 | 2,048 |
| BRIGHAM AND WOMEN'S HOSPITAL | 75 FRANCIS ST | BOSTON | MA | 02115 | 2,000 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. JEFFREY E BALL | 506 6TH ST | BROOKLYN | NY | 11215 | 168 |
| Dr. LORI ANN LESLIE | 1515 HOLCOMBE BLVD, UNIT 463 | HOUSTON | TX | 77030 | 139 |
| Dr. TATYANA A FELDMAN | 92 2ND ST | HACKENSACK | NJ | 07601 | 120 |
| Physician Name | Address | City | State | Zip Code | Total Hospitalizations ( Oct 2015 to Sep 2018 ) |
|---|---|---|---|---|---|
| Dr. LORI ANN LESLIE | 1515 HOLCOMBE BLVD, UNIT 463 | HOUSTON | TX | 77030 | 218 |
| Dr. MELISSA LEIGH LARSON | 1725 W HARRISON ST | CHICAGO | IL | 60612 | 194 |
| Dr. JEFFREY E BALL | 506 6TH ST | BROOKLYN | NY | 11215 | 194 |